Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Compare Drugs in Complement Inhibitor [EPC]

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
Drug Reports Deaths Death Rate Hosp. Life-Threat. Avg Age % Female
ECULIZUMAB 44,190 4,626 10.5% 12,421 819 42.6 yrs 59.5%
PEGCETACOPLAN 1,369 84 6.1% 252 23 65.4 yrs 70.5%
ZILUCOPLAN 441 23 5.2% 163 25 58.8 yrs 53.6%
AVACINCAPTAD PEGOL 202 3 1.5% 2 1 82.3 yrs 61.9%
RAVULIZUMAB 118 11 9.3% 89 16 48.4 yrs 56.3%

Head-to-Head Comparisons

ECULIZUMAB vs PEGCETACOPLAN ECULIZUMAB vs ZILUCOPLAN ECULIZUMAB vs AVACINCAPTAD PEGOL ECULIZUMAB vs RAVULIZUMAB PEGCETACOPLAN vs ZILUCOPLAN PEGCETACOPLAN vs AVACINCAPTAD PEGOL PEGCETACOPLAN vs RAVULIZUMAB ZILUCOPLAN vs AVACINCAPTAD PEGOL ZILUCOPLAN vs RAVULIZUMAB AVACINCAPTAD PEGOL vs RAVULIZUMAB
← Back to Complement Inhibitor [EPC] Class side effects →